ArticleTranslational andrology and urology2024
Combination of PARP and DNA methylation inhibitors as a potential personalized therapy for SETD2-mutated clear-cell renal cancers.
Ali Shahini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.